Clinical Trial Update: Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Erdafitinib (JNJ-42756493) for cancers with FGFR amplifications; the study includes advanced and refractory lymphoma, solid tumors, and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Multiple Myeloma
• Solid Tumors

Drugs mentioned

• BALVERSA (erdafitinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-06-18